Orbital pseudotumor

Summary

Orbital pseudotumor (MONDO:0004769) is a disease and 3 clinical trials. Top therapeutic interventions include prednisolone and triamcinolone. A subtype of chronic orbital inflammation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	orbital pseudotumor
Mondo ID	MONDO:0004769
MeSH	D016727
DOID	DOID:9369
SNOMED CT	72789009
UMLS	C0085270
MedGen	43140
Is cancer (heuristic)	no

Also known as: granuloma, plasma cell, orbital · inflammatory pseudotumor of orbit · inflammatory pseudotumor of orbit proper · inflammatory pseudotumor, orbital · inflammatory pseudotumors, orbital · orbital granuloma, plasma cell · orbital inflammatory pseudotumor · orbital inflammatory pseudotumors · orbital myositis · orbital pseudotumors · plasma cell granuloma, orbital · pseudotumor, inflammatory, orbital · pseudotumor, orbital · pseudotumor, orbital inflammatory · pseudotumors, orbital

Disease family

This is a subtype of chronic orbital inflammation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › disease of orbital part of eye adnexa › chronic orbital inflammation › orbital pseudotumor

Related subtypes (1): orbital granuloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Betamethasone	Phase 3
Prednisolone	Phase 3
Triamcinolone	Phase 3

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03958344	PHASE3	UNKNOWN	Intraorbital Injection Versus Oral Steroid in Anterior Idiopathic Orbital Inflammation
NCT01443000	Not specified	COMPLETED	Survey of Patients With Idiopathic Orbital Inflammation Syndrome
NCT02401906	Not specified	COMPLETED	MRI and Orbital Tumours (MEDORT)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PREDNISOLONE	4	1
TRIAMCINOLONE	4	1